Subtopic Deep Dive

TGF-β Inhibitors in Cancer Therapy
Research Guide

What is TGF-β Inhibitors in Cancer Therapy?

TGF-β inhibitors in cancer therapy are small molecules, antibodies, and traps that block TGF-β ligands or receptors to counteract pro-tumorigenic signaling in advanced cancers.

These inhibitors target TGF-β type I receptor kinase activity, such as SB-431542 (Laping et al., 2002, 646 citations), and enhance chemotherapy efficacy in triple-negative breast cancer (Bhola et al., 2013, 582 citations). Clinical trials evaluate their combination strategies to overcome TGF-β-mediated resistance. Over 10 key papers from 1994-2013 detail receptor specificity and signaling modulation.

Curated Papers

Key Challenges

Why It Matters

TGF-β inhibitors reverse immunosuppression and extracellular matrix deposition in tumors, improving chemotherapy outcomes in triple-negative breast cancer as shown by Bhola et al. (2013). SB-431542 blocks TGF-β1-induced matrix production (Laping et al., 2002), supporting fibrosis reduction in cancer microenvironments. Massagué et al. (2000) highlight TGF-β's role in growth control and cancer progression, making inhibitors critical for trials targeting Smad-mediated responses (Derynck et al., 1998).

Key Research Challenges

Toxicity from Systemic Inhibition

Blocking TGF-β broadly disrupts wound healing and immune homeostasis due to its dual tumor-suppressive and pro-tumor roles (Massagué et al., 2000). Clinical translation requires balancing efficacy against vascular side effects linked to ALK1 modulation (Oh et al., 2000). Dose optimization remains unresolved in ongoing trials.

Resistance via Pathway Crosstalk

Cancer cells develop resistance through Smad-independent signaling despite type I receptor blockade (Laping et al., 2002). Combinatorial strategies with chemotherapy show promise but face heterogeneous responses (Bhola et al., 2013). Signaling diversity complicates inhibitor specificity (Piek et al., 1999).

Limited Receptor Specificity

Type I receptors like ALK1 and others bind multiple TGF-β family members, reducing inhibitor precision (ten Dijke et al., 1994). Smad regulation varies by context, hindering targeted therapy (Moustakas et al., 2001). Antibody and trap development aims to improve selectivity.

Essential Papers

TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders

Joan Massagué, Stacy W. Blain, Roger S. Lo · 2000 · Cell · 2.4K citations

NEW EMBO MEMBERS REVIEW: Transcriptional control by the TGF-beta/Smad signaling system

Joan Massagué · 2000 · The EMBO Journal · 2.0K citations

Transcriptional Activators of TGF-β Responses: Smads

Rik Derynck, Ying E. Zhang, Xin‐Hua Feng · 1998 · Cell · 1.0K citations

Smad regulation in TGF-β signal transduction

Aristidis Moustakas, Serhiy Souchelnytskyi, Carl‐Henrik Heldin · 2001 · Journal of Cell Science · 922 citations

Smad proteins transduce signals from transforming growth factor-β (TGF-β) superfamily ligands that regulate cell proliferation, differentiation and death through activation of receptor serine/threo...

Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis

S. Paul Oh, Tsugio Seki, Kendrick A. Goss et al. · 2000 · Proceedings of the National Academy of Sciences · 855 citations

The activin receptor-like kinase 1 (ALK1) is a type I receptor for transforming growth factor-β (TGF-β) family proteins. Expression of ALK1 in blood vessels and mutations of the ALK1 gene in human ...

Specificity, diversity, and regulation in TGF‐β superfamily signaling

Ester Piek, Carl‐Henrik Heldin, Peter ten Dijke · 1999 · The FASEB Journal · 652 citations

ABSTRACT Transforming growth factor‐β (TGF‐β) superfamily members are multifunctional cell‐cell signaling proteins that play pivotal roles in tissue homeostasis and development of multicellular ani...

Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542

Nicholas J. Laping, Eugene T. Grygielko, Anil Mathur et al. · 2002 · Molecular Pharmacology · 646 citations

Reading Guide

Foundational Papers

Start with Massagué et al. (2000, 2365 citations) for TGF-β cancer overview, then Derynck et al. (1998, 1031 citations) on Smads, and ten Dijke et al. (1994, 552 citations) for receptor characterization to build signaling basics.

Recent Advances

Study Bhola et al. (2013, 582 citations) for chemotherapy combinations in TNBC and Laping et al. (2002, 646 citations) for SB-431542 as a prototype inhibitor in clinical contexts.

Core Methods

Core techniques: type I receptor kinase inhibition (SB-431542, Laping et al., 2002), Smad phosphorylation assays (Moustakas et al., 2001), and ALK1 modulation for angiogenesis (Oh et al., 2000).

How PapersFlow Helps You Research TGF-β Inhibitors in Cancer Therapy

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph to map 250M+ papers, starting from Massagué et al. (2000, 2365 citations) to find inhibitors like SB-431542 (Laping et al., 2002). exaSearch uncovers clinical trial data on TGF-β traps; findSimilarPapers links Bhola et al. (2013) to combination therapies.

Analyze & Verify

Analysis Agent employs readPaperContent on Laping et al. (2002) to extract SB-431542 IC50 values, then runPythonAnalysis with pandas to quantify dose-responses across Smad papers (Moustakas et al., 2001). verifyResponse via CoVe and GRADE grading verifies claims on chemotherapy synergy (Bhola et al., 2013) against contradictions in Massagué reviews.

Synthesize & Write

Synthesis Agent detects gaps in inhibitor specificity from ten Dijke et al. (1994) versus recent trials; Writing Agent uses latexEditText, latexSyncCitations for Bhola et al. (2013), and latexCompile to generate therapy review manuscripts. exportMermaid visualizes TGF-β/Smad inhibitor pathways from Derynck et al. (1998).

Use Cases

"Analyze dose-response curves of SB-431542 from Laping 2002 and similar inhibitors."

Research Agent → searchPapers('SB-431542 TGF-β') → Analysis Agent → readPaperContent(Laping et al., 2002) → runPythonAnalysis(pandas plot IC50 vs. Smad phosphorylation) → matplotlib graph of efficacy/toxicity trends.

"Draft LaTeX review on TGF-β inhibitors enhancing TNBC chemotherapy."

Synthesis Agent → gap detection(Bhola et al., 2013 + Massagué 2000) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile(PDF with figures) → output formatted review manuscript.

"Find code for modeling TGF-β receptor kinase inhibition simulations."

Research Agent → paperExtractUrls(Smad signaling papers) → paperFindGithubRepo → githubRepoInspect(TGF-β models) → runPythonAnalysis(NumPy simulate SB-431542 kinetics from Laping 2002) → exportCsv(dose-response data).

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers(50+ TGF-β inhibitor trials) → citationGraph(Massagué et al., 2000 hub) → GRADE evidence tables on efficacy (Bhola et al., 2013). DeepScan applies 7-step analysis with CoVe checkpoints to verify toxicity claims from Oh et al. (2000). Theorizer generates hypotheses on Smad3-specific inhibitors (Flanders, 2004) from pathway papers.

Try Doxa for TGF-β Inhibitors in Cancer Therapy Research

Frequently Asked Questions

What defines TGF-β inhibitors in cancer therapy?

They are small molecules like SB-431542, antibodies, and traps blocking TGF-β ligands or receptors such as type I kinases to halt pro-tumor signaling (Laping et al., 2002; ten Dijke et al., 1994).

What are key methods for TGF-β inhibition?

Methods include kinase inhibitors targeting type I receptors (Laping et al., 2002), ligand traps, and antibodies; they disrupt Smad phosphorylation and transcriptional responses (Moustakas et al., 2001; Derynck et al., 1998).

What are landmark papers?

Massagué et al. (2000, 2365 citations) reviews TGF-β in cancer; Laping et al. (2002, 646 citations) introduces SB-431542; Bhola et al. (2013, 582 citations) shows chemotherapy synergy in TNBC.

What open problems exist?

Challenges include systemic toxicity, resistance via crosstalk, and achieving receptor specificity amid signaling diversity (Oh et al., 2000; Piek et al., 1999; Bhola et al., 2013).